-
Product Insights
NewNet Present Value Model: Antengene Corp Ltd’s Eltanexor
Empower your strategies with our Net Present Value Model: Antengene Corp Ltd's Eltanexor report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Antengene Corp Ltd’s Onatasertib
Empower your strategies with our Net Present Value Model: Antengene Corp Ltd's Onatasertib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Antengene Corp Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Antengene Corp Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATG-101 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATG-101 in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATG-101 in Cervical Cancer Drug Details: ATG-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATG-101 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATG-101 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATG-101 in Gastric Cancer Drug Details: ATG-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATG-101 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATG-101 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATG-101 in Glioblastoma Multiforme (GBM) Drug Details: ATG-101 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATG-101 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATG-101 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATG-101 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATG-101 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATG-101 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATG-101 in Triple-Negative Breast Cancer (TNBC) Drug Details: ATG-101...
-
Product Insights
Cytokine Release Syndrome (Cytokine Storm) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cytokine Release Syndrome (Cytokine Storm) - Drugs In Development, 2023’, provides an overview of the Cytokine Release Syndrome (Cytokine Storm) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cytokine Release Syndrome (Cytokine Storm), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...